Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;121(9):e20240252.
doi: 10.36660/abc.20240252.

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

[Article in Portuguese, English]
Affiliations
Review

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

[Article in Portuguese, English]
Ricardo Stein et al. Arq Bras Cardiol. 2024 Sep.

Abstract

Despite significant advances in the management of coronary artery disease (CAD) and reductions in annual mortality rates in recent decades, this disease remains the leading cause of death worldwide. Consequently, there is an ongoing need for efforts to address this situation. Current clinical algorithms to identify at-risk patients are particularly inaccurate in moderate-risk individuals. For this reason, the need for ancillary tests has been suggested, including predictive genetic screening. As genetic studies rapidly expand and genomic data becomes more accessible, numerous genetic risk scores have been proposed to identify and evaluate an individual's susceptibility to developing diseases, including CAD. The field of genetics has indeed made substantial contributions to risk prediction, particularly in cases where children have parents with premature CAD, resulting in an increased risk of up to 75%. The polygenic risk scores (PRSs) have emerged as a potentially valuable tool for understanding and stratifying an individual's genetic risk. The PRS is calculated as a weighted sum of single-nucleotide variants present throughout the human genome, identifiable through genome-wide association studies, and associated with various cardiometabolic diseases. The use of PRSs holds promise, as it enables the development of personalized strategies for preventing or diagnosing specific pathologies early. Furthermore, it can complement existing clinical scores, increasing the accuracy of individual risk prediction. Consequently, the application of PRSs has the potential to impact the costs and adverse outcomes associated with CAD positively. This narrative review provides an overview of the role of PRSs in the context of CAD.

Apesar dos avanços significativos no tratamento da doença arterial coronariana (DAC) e das reduções nas taxas de mortalidade anuais nas últimas décadas, a DAC continua sendo a principal causa de morte no mundo. Consequentemente, há uma necessidade contínua de esforços para abordar essa situação. Os algoritmos clínicos atuais para identificar pacientes em risco são particularmente imprecisos para indivíduos de risco moderado. Por esse motivo, foi sugerido que são necessários testes auxiliares, incluindo triagem genética preditiva. À medida que os estudos genéticos se expandem rapidamente e os dados genômicos se tornam mais acessíveis, diversos escores de risco genético têm sido propostos para identificar e avaliar a suscetibilidade de um indivíduo ao desenvolvimento de doenças, incluindo a DAC. De fato, o campo da genética tem contribuído substancialmente para a previsão de risco, particularmente nos casos em que as crianças têm genitores com DAC prematura, resultando em um risco aumentado de até 75%. Os escores de risco poligênico (PRSs, do inglês polygenic risk scores) surgiram como uma ferramenta potencialmente valiosa para compreender e estratificar o risco genético de um indivíduo. O PRS é calculado como uma soma ponderada de variantes de nucleotídeo único presentes em todo o genoma humano, identificáveis por meio de estudos de associação genômica ampla, e associadas a várias doenças cardiometabólicas. O uso dos PRSs é promissor, pois permite o desenvolvimento de estratégias personalizadas para prevenir ou diagnosticar patologias específicas de forma precoce. Ademais, seu uso é capaz de complementar os escores clínicos existentes, aumentando a precisão da previsão de risco individual. Consequentemente, a aplicação dos PRSs tem o potencial de impactar positivamente os custos e os desfechos adversos associados à DAC. A presente revisão narrativa oferece uma visão ampla do papel dos PRSs no contexto da DAC.

PubMed Disclaimer

Conflict of interest statement

Potencial conflito de interesse: Não há conflito com o presente artigo

Figures

Figura Central
Figura Central. : Escores de Risco Poligênico: O Próximo Passo para Melhorar a Estratificação de Risco na Doença Arterial Coronariana?
Figura 1
Figura 1. – Aspectos essenciais de uma análise de escore de risco poligênico. AUC: área sob a curva ROC (receiver operator characteristic); GWAS: estudos de associação genômica ampla; LD: desequilíbrio de ligação; PRS: escore de risco poligênico; SNP: polimorfismos de nucleotídeo único.
Central Illustration
Central Illustration. : Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?
Figure 1
Figure 1. – Essential aspects of a polygenic risk score analysis. AUC: area under the receiver operating characteristic curve; GWAS: genome-wide association studies; LD: linkage disequilibrium; OR: odds ratio; PRS: polygenic risk score; SNPs: single nucleotide polymorphisms.

Similar articles

Cited by

  • Familial Combined Hyperlipidemia: Myth or Reality?
    Brouwers MCGJ, Klop B, Ribalta J, Castro Cabezas M. Brouwers MCGJ, et al. Curr Atheroscler Rep. 2025 Apr 1;27(1):45. doi: 10.1007/s11883-025-01289-9. Curr Atheroscler Rep. 2025. PMID: 40167575 Free PMC article. Review.

References

    1. Aragam KG, Dobbyn A, Judy R, Chaffin M, Chaudhary K, Hindy G, et al. Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. J Am Coll Cardiol. 2020;75(22):2769–2780. doi: 10.1016/j.jacc.2020.04.027. - DOI - PMC - PubMed
    1. Chen Y, Chen S, Han Y, Xu Q, Zhao X. Elevated ApoB/apoA-1 is Associated with In-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction. Diabetes Metab Syndr Obes. 2023;16:3501–3512. doi: 10.2147/DMSO.S433876. - DOI - PMC - PubMed
    1. Laway BA, Rasool A, Baba MS, Misgar RA, Bashir MI, Wani AI, et al. High Prevalence of Coronary Artery Calcification and Increased Risk for Coronary Artery Disease in Patients with Sheehan Syndrome-A Case-control Study. Clin Endocrinol. 2023;98(3):375–382. doi: 10.1111/cen.14871. - DOI - PubMed
    1. Akintoye E, Afonso L, Jayanna MB, Bao W, Briasoulis A, Robinson J. Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights from 3 Large Prospective Cohorts. J Am Heart Assoc. 2021;10(12):e019589. doi: 10.1161/JAHA.120.019589. - DOI - PMC - PubMed
    1. Cole J, Zubirán R, Wolska A, Jialal I, Remaley AT. Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change? 5737J Clin Med. 2023;12(17) doi: 10.3390/jcm12175737. - DOI - PMC - PubMed